Orforglipron
Aliases: LY3502970 · oral non-peptide GLP-1RA
Orforglipron is a oral peptide/small molecule peptide targeting GLP-1R, developed by Eli Lilly for undisclosed indications. As of Aug 15, 2024, its highest verified stage is Phase 3.
Phase 3· verified Aug 15, 2024
Identity
Development timeline
Trials
View all →| Registry ID | Phase | Status | Enrollment | Completion |
|---|---|---|---|---|
| Lilly-orforglipron-Ph3 | Phase 3 | Recruiting | 3000 | Sep 1, 2026 |